Menu
Search
|

Menu

Close
X

Cancer Genetics Inc CGIX.OQ (NASDAQ Stock Exchange Capital Market)

0.19 USD
+0.00 (+1.75%)
As of 1:41 PM EDT
Previous Close 0.19
Open 0.19
Volume 457,691
3m Avg Volume 318,412
Today’s High 0.19
Today’s Low 0.18
52 Week High 1.29
52 Week Low 0.15
Shares Outstanding (mil) 19.79
Market Capitalization (mil) 53.93
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY19
7
FY18
27
FY17
29
FY16
27
EPS (USD)
FY19
-0.094
FY18
-0.746
FY17
-0.352
FY16
-1.039
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
1.96
7.92
Price to Book (MRQ)
vs sector
2.89
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
41.81
14.56
LT Debt to Equity (MRQ)
vs sector
29.66
10.21
Return on Investment (TTM)
vs sector
-57.22
14.49
Return on Equity (TTM)
vs sector
-78.97
15.79

EXECUTIVE LEADERSHIP

John Pappajohn
Non-Executive Chairman of the Board, Since 2014
Salary: --
Bonus: --
John Roberts
President, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Glenn Miles
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Jane Houldsworth
Vice President - Research & Development, Since 2011
Salary: $275,192.00
Bonus: $26,500.00
Raju Chaganti
Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Healthcare Facilities & Services
Address:

201 State Rt 17 Fl 2
RUTHERFORD   NJ   07070-2597

Phone: +1201.5289200

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. Through its subsidiary, the Company offers preclinical test systems. The Company offers discovery services to the pharmaceutical industry, biotechnology companies and academic research centers. The Company provides the tools and testing methods for companies and researchers to identify new molecular- and biomarker-based indicators for disease and to determine the pharmacogenomics, toxicity and efficacy of therapeutic candidate compounds. Its discovery services include development of both xenograft and syngeneic animal models, toxicology and genetic toxicology services, pharmacology testing, pathology services, and validation of biomarkers for diseases including cancers. It also provides consulting, guidance and preparation of samples.

SPONSORED STORIES